Syndax Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapies for various cancer indications. The company's lead product candidate is Entinostat, which is in Phase 3 clinical trial for the treatment of hormone receptor positive or HR+, human epidermal growth factor receptor 2 negative or HER2-, and breast cancer; and Phase 1b/2 clinical trial. It also develops SNDX-6352, an immunoglobulin G subclass 4 isotype that binds to the ligand binding domain of CSF-1R, blocking the binding and consequent activation by natural ligands interleukin-34 and colony stimulating factor-1, and disrupting tumor-associated macrophages activity. Syndax Pharmaceuticals, Inc. has clinical collaborations with MSD International GmbH, Genentech, Inc., Merck KGaA, Pfizer, and AstraZeneca; collaborative research and development agreement with National Cancer Institute; clinical trial agreement with Eastern Cooperative Oncology Group; and license agreement with Kyowa Hakko Kirin Co., Ltd. The company was founded in 2005 and is headquartered in Waltham, Massachusetts.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:SNDX
CUSIPN/A
Phone781-419-1400
Debt
Debt-to-Equity RatioN/A
Current Ratio7.06
Quick Ratio7.06
Price-To-Earnings
Trailing P/E Ratio-2.51
Forward P/E Ratio-2.10
P/E GrowthN/A
Sales & Book Value
Annual Sales$2.11 million
Price / Sales85.20
Cash FlowN/A
Price / CashN/A
Book Value$4.28 per share
Price / Book1.70
Profitability
EPS (Most Recent Fiscal Year)($2.90)
Net Income$-60,800,000.00
Net Margins-3,081.07%
Return on Equity-67.69%
Return on Assets-52.09%
Miscellaneous
Employees44
Outstanding Shares24,710,000
Market Cap$181.59
Syndax Pharmaceuticals (NASDAQ:SNDX) Frequently Asked Questions
What is Syndax Pharmaceuticals' stock symbol?
Syndax Pharmaceuticals trades on the NASDAQ under the ticker symbol "SNDX."
How were Syndax Pharmaceuticals' earnings last quarter?
Syndax Pharmaceuticals Inc (NASDAQ:SNDX) posted its earnings results on Tuesday, May, 8th. The company reported ($0.79) EPS for the quarter, topping the consensus estimate of ($0.96) by $0.17. The business had revenue of $0.38 million for the quarter. Syndax Pharmaceuticals had a negative net margin of 3,081.07% and a negative return on equity of 67.69%. View Syndax Pharmaceuticals' Earnings History.
When is Syndax Pharmaceuticals' next earnings date?
What price target have analysts set for SNDX?
7 brokerages have issued 12 month price targets for Syndax Pharmaceuticals' shares. Their predictions range from $20.00 to $40.00. On average, they anticipate Syndax Pharmaceuticals' stock price to reach $26.7143 in the next twelve months. This suggests a possible upside of 267.2% from the stock's current price. View Analyst Ratings for Syndax Pharmaceuticals.
What is the consensus analysts' recommendation for Syndax Pharmaceuticals?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Syndax Pharmaceuticals in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
What are Wall Street analysts saying about Syndax Pharmaceuticals stock?
Here are some recent quotes from research analysts about Syndax Pharmaceuticals stock:
- 1. HC Wainwright analysts commented, "Valuation: We base our $30 price target on probability-adjusted revenue forecasts for entinostat in combination with other drugs in advanced HR+, HER2- breast cancer, NSCLC, and metastatic melanoma. We use the net present value of our revenue forecast through 2027, apply a 35% POS for HR+, HER2- breast cancer, and 10% POS for NSCLC and melanoma, with a 3x price/sales multiple, and we value the early stage pipeline at $10 million, the amount of the upfront payments the company made to acquire the menin inhibitors and SNDX-6352, to arrive at our price target." (7/12/2018)
- 2. According to Zacks Investment Research, "Syndax Pharmaceuticals, Inc. is a biopharmaceutical company which focused on the development and commercialization of entinostat, an epigenetic therapy for treatment-resistant cancers. The Company's product pipeline includes ENCORE 601, ENCORE 602, J1353, NCI-7870, NCI-9844, E2112, NCI-8871 and NCI-9253 which are in clinical trial stage. Syndax Pharmaceuticals, Inc. is based in WALTHAM, United States. " (5/15/2018)
Are investors shorting Syndax Pharmaceuticals?
Syndax Pharmaceuticals saw a increase in short interest in June. As of June 15th, there was short interest totalling 2,075,485 shares, an increase of 59.6% from the May 31st total of 1,300,054 shares. Based on an average trading volume of 366,299 shares, the short-interest ratio is currently 5.7 days. Currently, 10.7% of the company's shares are sold short. View Syndax Pharmaceuticals' Current Options Chain.
Who are some of Syndax Pharmaceuticals' key competitors?
Some companies that are related to Syndax Pharmaceuticals include AC Immune (ACIU), Cara Therapeutics (CARA), Aptinyx (APTX), GlycoMimetics (GLYC), Abeona Therapeutics (ABEO), Vectura Group (VEGPF), Viking Therapeutics (VKTX), Kura Oncology (KURA), Urogen Pharma (URGN), Collegium Pharmaceutical (COLL), Dova Pharmaceuticals (DOVA), Odonate Therapeutics (ODT), Aclaris Therapeutics (ACRS), Dicerna Pharmaceuticals (DRNA) and ChemoCentryx (CCXI).
Who are Syndax Pharmaceuticals' key executives?
Syndax Pharmaceuticals' management team includes the folowing people:
- Dr. Briggs W. Morrison, CEO & Director (Age 58)
- Mr. Michael A. Metzger, Pres & COO (Age 47)
- Mr. Richard P. Shea, CFO & Treasurer (Age 66)
- Dr. Michael L. Meyers, Chief Medical Officer & Sr. VP (Age 67)
- Dr. Peter Ordentlich, Co-Founder & Chief Scientific Officer (Age 49)
When did Syndax Pharmaceuticals IPO?
(SNDX) raised $66 million in an IPO on Thursday, March 3rd 2016. The company issued 4,400,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley and Citigroup acted as the underwriters for the IPO and JMP Securities and Oppenheimer & Co. were co-managers.
Has Syndax Pharmaceuticals been receiving favorable news coverage?
News headlines about SNDX stock have been trending somewhat positive on Thursday, Accern Sentiment Analysis reports. Accern identifies negative and positive media coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Syndax Pharmaceuticals earned a news sentiment score of 0.11 on Accern's scale. They also assigned media headlines about the company an impact score of 48.55 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.
How do I buy shares of Syndax Pharmaceuticals?
Shares of SNDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Syndax Pharmaceuticals' stock price today?
One share of SNDX stock can currently be purchased for approximately $7.2750.
How big of a company is Syndax Pharmaceuticals?
Syndax Pharmaceuticals has a market capitalization of $181.59 million and generates $2.11 million in revenue each year. The company earns $-60,800,000.00 in net income (profit) each year or ($2.90) on an earnings per share basis. Syndax Pharmaceuticals employs 44 workers across the globe.
How can I contact Syndax Pharmaceuticals?
Syndax Pharmaceuticals' mailing address is 35 GATEHOUSE DRIVE BUILDING D FLOOR 3, WALTHAM MA, 02451. The company can be reached via phone at 781-419-1400 or via email at [email protected]
MarketBeat Community Rating for Syndax Pharmaceuticals (NASDAQ SNDX)
MarketBeat's community ratings are surveys of what our community members think about Syndax Pharmaceuticals and other stocks. Vote "Outperform" if you believe SNDX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SNDX will underperform the S&P 500 over the long term. You may vote once every thirty days.
